Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-α and ribavirin treatment

A Corrigendum to this article was published on 18 November 2009

Abstract

Depression and fatigue are frequent side effects of interferon-α (IFN-α) treatment, and there is compelling evidence that the inflammatory response system (including interleukin-6, IL-6) and the serotonergic system is important in the pathophysiology of such symptoms. Functional polymorphisms in the promoter region of the IL-6 gene (rs1800795) and serotonin transporter gene (5-HTTLPR) have been identified as regulating these systems. The present study aimed to determine if these polymorphisms were associated with the development of depression and fatigue during IFN-α and ribavirin treatment. Ninety-eight Caucasian patients receiving pegylated IFN-α and ribavirin treatment for chronic hepatitis C virus at King's College Hospital, London, and Emory University Hospital, Atlanta, participated in this prospective cohort study. Symptoms of depression and fatigue were measured before treatment and at weeks 4, 8, 12 and 24 during treatment. The ‘low IL-6’ synthesizing genotype (CC) was associated with significantly fewer symptoms of depression (effect size=0.7 at week 24; F=9.4, d.f.=436, P=0.002). The ‘high transcription’ serotonin transporter (5-HTT) genotype (LL) was also associated with significantly fewer symptoms of depression, but with a much smaller effect (effect size=0.2 at week 24; F=4.5, d.f.=436, P=0.03). Neither polymorphisms were associated with symptoms of fatigue (IL-6: F=1.2, d.f.=430, P=0.2; 5-HTT: F=0.5, d.f.=430, P=0.5). The smaller effects of the 5-HTT polymorphism on depression may be explained by an interaction between the genes (F=5.0, d.f.=434, P=0.02): the ‘protective’ effect of the 5-HTTLPR polymorphism was evident only in the presence of the ‘low IL-6’ genotype (F=5.4, d.f.=64, P=0.02), not in the presence of the ‘high IL-6’ genotype (F=2.2, d.f.=369, P=0.1). The association between the IL-6 polymorphism and reduced risk of depressive symptoms confirms the role of the inflammatory response system in the pathophysiology of IFN-α-induced depression; in contrast, the effect of the 5-HTT gene was small and perhaps dependent on the status of the inflammatory response.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–965.

    Article  CAS  PubMed  Google Scholar 

  2. Maddock C, Landau S, Barry K, Maulayah P, Hotopf M, Cleare AJ et al. Psychopathological symptoms during interferon-alpha and ribavirin treatment: effects on virologic response. Mol Psychiatry 2005; 10: 332–333.

    Article  CAS  PubMed  Google Scholar 

  3. Raison CL, Broadwell SD, Borisov AS, Manatunga AK, Capuron L, Woolwine BJ et al. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun 2005; 19: 23–27.

    Article  CAS  PubMed  Google Scholar 

  4. Loftis JM, Hauser P, Rifai MA . The association between viral clearance and depression in patients with hepatitis C receiving interferon-alpha and ribavirin. Brain Behav Immun 2005; 19: 271–272.

    Article  PubMed  Google Scholar 

  5. Schafer A, Scheurlen M, Weissbrich B, Schottker K, Kraus MR . Sustained virological response in the antiviral therapy of chronic hepatitis C: is there a predictive value of interferon-induced depression? Chemotherapy 2007; 53: 292–299.

    Article  PubMed  Google Scholar 

  6. Raison CL, Capuron L, Miller AH . Depressive symptoms and viral clearance: in response. Brain Behav Immun 2005; 19: 273–274.

    Article  Google Scholar 

  7. Pfeffer LM, Dinarello CA, Herberman RB, Williams BR, Borden EC, Bordens R et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 1998; 58: 2489–2499.

    CAS  PubMed  Google Scholar 

  8. Biro L, Varga L, Par A, Nemesanszky E, Telegdy L, Ibranyi E et al. C5b-9 and interleukin-6 in chronic hepatitis C. Surrogate markers predicting short-term response to interferon alpha-2b. Scand J Gastroenterol 2000; 35: 1092–1096.

    Article  CAS  PubMed  Google Scholar 

  9. Kido M, Kumagai N, Toda K, Tsuchimoto K, Komiyama T . Differential induction of serum interleukin-6 and -12 by interferon-alpha and -beta administration in chronic hepatitis C patients. Hepatol Res 2003; 27: 101–108.

    Article  CAS  PubMed  Google Scholar 

  10. Dantzer R . Cytokine-induced sickness behavior: where do we stand? Brain Behav Immun 2001; 15: 7–24.

    Article  CAS  PubMed  Google Scholar 

  11. Bonaccorso S, Puzella A, Marino V, Pasquini M, Biondi M, Artini M et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res 2001; 105: 45–55.

    Article  CAS  PubMed  Google Scholar 

  12. Wichers MC, Kenis G, Leue C, Koek G, Robaeys G, Maes M . Baseline immune activation as a risk factor for the onset of depression during interferon-alpha treatment. Biol Psychiatry 2006; 60: 77–79.

    Article  CAS  PubMed  Google Scholar 

  13. Vollmer-Conna U, Fazou C, Cameron B, Li H, Brennan C, Luck L et al. Production of pro-inflammatory cytokines correlates with the symptoms of acute sickness behaviour in humans. Psychol Med 2004; 34: 1289–1297.

    Article  CAS  PubMed  Google Scholar 

  14. Maes M, Meltzer HY, Bosmans E, Bergmans R, Vandoolaeghe E, Ranjan R et al. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord 1995; 34: 301–309.

    Article  CAS  PubMed  Google Scholar 

  15. Sluzewska A, Rybakowski J, Bosmans E, Sobieska M, Berghmans R, Maes M et al. Indicators of immune activation in major depression. Psychiatry Res 1996; 64: 161–167.

    Article  CAS  PubMed  Google Scholar 

  16. Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H . Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997; 9: 853–858.

    Article  CAS  PubMed  Google Scholar 

  17. Gaab J, Rohleder N, Heitz V, Engert V, Schad T, Schurmeyer TH et al. Stress-induced changes in LPS-induced pro-inflammatory cytokine production in chronic fatigue syndrome. Psychoneuroendocrinology 2005; 30: 188–198.

    Article  CAS  PubMed  Google Scholar 

  18. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369–1376.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Fife BL . The role of constructed meaning in adaptation to the onset of life-threatening illness. Soc Sci Med 2005; 61: 2132–2143.

    Article  PubMed  Google Scholar 

  20. Antonicelli R, Olivieri F, Bonafe M, Cavallone L, Spazzafumo L, Marchegiani F et al. The interleukin-6-174 G>C promoter polymorphism is associated with a higher risk of death after an acute coronary syndrome in male elderly patients. Int J Cardiol 2005; 103: 266–271.

    Article  PubMed  Google Scholar 

  21. DeMichele A, Martin AM, Mick R, Gor P, Wray L, Klein-Cabral M et al. Interleukin-6-174G → C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res 2003; 63: 8051–8056.

    CAS  PubMed  Google Scholar 

  22. Wichers MC, Maes M . The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. J Psychiatry Neurosci 2004; 29: 11–17.

    PubMed  PubMed Central  Google Scholar 

  23. King NJ, Thomas SR . Molecules in focus: indoleamine 2,3-dioxygenase. Int J Biochem Cell Biol 2007; 39: 2167–2172.

    Article  CAS  PubMed  Google Scholar 

  24. Wirleitner B, Neurauter G, Schrocksnadel K, Frick B, Fuchs D . Interferon-gamma-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr Med Chem 2003; 10: 1581–1591.

    Article  CAS  PubMed  Google Scholar 

  25. Russo S, Kema IP, Fokkema MR, Boon JC, Willemse PH, de Vries EG et al. Tryptophan as a link between psychopathology and somatic states. Psychosom Med 2003; 65: 665–671.

    Article  CAS  PubMed  Google Scholar 

  26. Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack MA, Der M et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 1992; 115 (Part 5): 1249–1273.

    Article  PubMed  Google Scholar 

  27. Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpe S, Maes M . IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005; 10: 538–544.

    Article  CAS  PubMed  Google Scholar 

  28. Mann JJ . Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior. Neuropsychopharmacology 1999; 21: 99S–105S.

    Article  CAS  PubMed  Google Scholar 

  29. Stahl SM . Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 1998; 51: 215–235.

    Article  CAS  PubMed  Google Scholar 

  30. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301: 386–389.

    Article  CAS  PubMed  Google Scholar 

  31. Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D et al. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996; 66: 2621–2624.

    Article  CAS  PubMed  Google Scholar 

  32. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274: 1527–1531.

    Article  CAS  PubMed  Google Scholar 

  33. Heinz A, Jones DW, Mazzanti C, Goldman D, Ragan P, Hommer D et al. A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity. Biol Psychiatry 2000; 47: 643–649.

    Article  CAS  PubMed  Google Scholar 

  34. Hariri AR, Mattay VS, Tessitore A, Kolachana B, Fera F, Goldman D et al. Serotonin transporter genetic variation and the response of the human amygdala. Science 2002; 297: 400–403.

    Article  CAS  PubMed  Google Scholar 

  35. Anguelova M, Benkelfat C, Turecki G . A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: II. Suicidal behavior. Mol Psychiatry 2003; 8: 646–653.

    Article  CAS  PubMed  Google Scholar 

  36. Lerer B, Macciardi F . Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directions. Int J Neuropsychopharmacol 2002; 5: 255–275.

    Article  CAS  PubMed  Google Scholar 

  37. Serretti A, Kato M, De Ronchi D, Kinoshita T . Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 2007; 12: 247–257.

    Article  CAS  PubMed  Google Scholar 

  38. Nakamura M, Ueno S, Sano A, Tanabe H . The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol Psychiatry 2000; 5: 32–38.

    Article  CAS  PubMed  Google Scholar 

  39. Raison CL, Broadwell SD, Borisov AS, Manatunga AK, Capuron L, Woolwine BJ et al. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun 2005; 19: 23–27.

    Article  CAS  PubMed  Google Scholar 

  40. Lewis G, Pelosi AJ, Araya R, Dunn G . Measuring psychiatric disorder in the community: a standardized assessment for use by lay interviewers. Psychol Med 1992; 22: 465–486.

    Article  CAS  PubMed  Google Scholar 

  41. First M, Spitzer R, Gibbon M, Williams J . Structured Clinical Interview for DSM-IV Axis I Disorders. American Psychiatric Association: Washington, DC, 1997.

    Google Scholar 

  42. Maddock C, Baita A, Orru MG, Sitzia R, Costa A, Muntoni E et al. Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms. J Psychopharmacol 2004; 18: 41–46.

    Article  CAS  PubMed  Google Scholar 

  43. Pariante CM, Orru MG, Baita A, Farci MG, Carpiniello B . Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet 1999; 354: 131–132.

    Article  CAS  PubMed  Google Scholar 

  44. Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 2005; 66: 41–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J . An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561–571.

    Article  CAS  PubMed  Google Scholar 

  46. Zung WW . A Self-rating Depression Scale. Arch Gen Psychiatry 1965; 12: 63–70.

    Article  CAS  PubMed  Google Scholar 

  47. Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D et al. Development of a fatigue scale. J Psychosom Res 1993; 37: 147–153.

    Article  CAS  PubMed  Google Scholar 

  48. Freeman B, Smith N, Curtis C, Huckett L, Mill J, Craig IW . DNA from buccal swabs recruited by mail: evaluation of storage effects on long-term stability and suitability for multiplex polymerase chain reaction genotyping. Behav Genet 2003; 33: 67–72.

    Article  CAS  PubMed  Google Scholar 

  49. Beitchman JH, Baldassarra L, Mik H, De Luca V, King N, Bender D et al. Serotonin transporter polymorphisms and persistent, pervasive childhood aggression. Am J Psychiatry 2006; 163: 1103–1105.

    Article  PubMed  Google Scholar 

  50. Yoshida K, Alagbe O, Wang X, Woolwine B, Thornbury M, Raison CL et al. Promoter polymorphisms of the interferon-alpha receptor gene and development of interferon-induced depressive symptoms in patients with chronic hepatitis C: preliminary findings. Neuropsychobiology 2005; 52: 55–61.

    Article  CAS  PubMed  Google Scholar 

  51. Matsuyama N, Mishiro S, Sugimoto M, Furuichi Y, Hashimoto M, Hijikata M et al. The dinucleotide microsatellite polymorphism of the IFNAR1 gene promoter correlates with responsiveness of hepatitis C patients to interferon. Hepatol Res 2003; 25: 221–225.

    Article  CAS  PubMed  Google Scholar 

  52. Carlo-Stella N, Badulli C, De Silvestri A, Bazzichi L, Martinetti M, Lorusso L et al. A first study of cytokine genomic polymorphisms in CFS: positive association of TNF-857 and IFNgamma 874 rare alleles. Clin Exp Rheumatol 2006; 24: 179–182.

    CAS  PubMed  Google Scholar 

  53. Narita M, Nishigami N, Narita N, Yamaguti K, Okado N, Watanabe Y et al. Association between serotonin transporter gene polymorphism and chronic fatigue syndrome. Biochem Biophys Res Commun 2003; 311: 264–266.

    Article  CAS  PubMed  Google Scholar 

  54. Yamamoto S, Ouchi Y, Onoe H, Yoshikawa E, Tsukada H, Takahashi H et al. Reduction of serotonin transporters of patients with chronic fatigue syndrome. Neuroreport 2004; 15: 2571–2574.

    Article  CAS  PubMed  Google Scholar 

  55. Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002; 26: 643–652.

    Article  CAS  PubMed  Google Scholar 

  56. Schaefer M, Hinzpeter A, Mohmand A, Janssen G, Pich M, Schwaiger M et al. Hepatitis C treatment in ‘difficult-to-treat’ psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology 2007; 46: 991–998.

    Article  CAS  PubMed  Google Scholar 

  57. Kraus MR, Schafer A, Al Taie O, Scheurlen M . Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepat 2005; 12: 96–100.

    Article  CAS  PubMed  Google Scholar 

  58. Capuron L, Raison CL, Musselman DL, Lawson DH, Nemeroff CB, Miller AH . Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry 2003; 160: 1342–1345.

    Article  PubMed  Google Scholar 

  59. Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R . Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002; 7: 468–473.

    CAS  PubMed  Google Scholar 

  60. Neumeister A, Hu XZ, Luckenbaugh DA, Schwarz M, Nugent AC, Bonne O et al. Differential effects of 5-HTTLPR genotypes on the behavioral and neural responses to tryptophan depletion in patients with major depression and controls. Arch Gen Psychiatry 2006; 63: 978–986.

    Article  CAS  PubMed  Google Scholar 

  61. Moreno FA, Rowe DC, Kaiser B, Chase D, Michaels T, Gelernter J et al. Association between a serotonin transporter promoter region polymorphism and mood response during tryptophan depletion. Mol Psychiatry 2002; 7: 213–216.

    Article  CAS  PubMed  Google Scholar 

  62. Raison CL, Capuron L, Miller AH . Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006; 27: 24–31.

    CAS  PubMed  Google Scholar 

  63. Capuron L, Ravaud A . Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state. N Engl J Med 1999; 340: 1370.

    Article  CAS  PubMed  Google Scholar 

  64. Rosenstein DL, Lerner D, Cai J, Capuron L, Ravaud A . More on the depressive effects of interferon Alfa. N Engl J Med 1999; 341: 849–850.

    Article  CAS  PubMed  Google Scholar 

  65. Pariante CM, Landau S, Carpiniello B . Interferon alfa-induced adverse effects in patients with a psychiatric diagnosis. N Engl J Med 2002; 347: 148–149.

    Article  PubMed  Google Scholar 

  66. Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 2006; 78: 815–826.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Dr CM Pariante and the UK arm of this study were funded by grants from the Guy's and St Thomas’ Charitable Foundation, the NIHR Specialist Biomedical Research Centre for Mental Health at South London and Maudsley NHS Trust and Institute of Psychiatry (Kings’ College London), the UK Medical Research Council and the NARSAD. The USA arm of the study was funded by grant numbers K05 MH069124 and R01 MH60723 (National Institute of Mental Health), a NARSAD Independent Investigator Award to J Cubells, and by support from the Schering-Plough corporation.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to C M Pariante.

Additional information

Disclosure/Conflict of Interest

Professor AH Miller has served as a consultant or an advisory board member for Schering-Plough and Centocor, and has received research funding from Janssen/Johnson and Johnson, GlaxoSmithKline and Schering-Plough.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bull, S., Huezo-Diaz, P., Binder, E. et al. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-α and ribavirin treatment. Mol Psychiatry 14, 1095–1104 (2009). https://doi.org/10.1038/mp.2008.48

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/mp.2008.48

Keywords

This article is cited by

Search

Quick links